Who does NOT need PARP inhibition?

Date

04 May 2019

Session

Metastatic breast cancer: TNBC

Presenters

Giuseppe Curigliano

Authors

G. Curigliano

Author affiliations

  • Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, 20141 - Milan/IT
More

Resources

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings